Factor Model (net -1.0)
Factor Model
net -1.0 2.8 / 10Analysts raise targets on FY27 growth promise
Watch: Q3 results will be the test — if the downward guidance proves deeper than expected, those FY27 projections lose credibility fast. Watch for any commentary on end-market demand and margin recovery timing.
Bio-Techne beat earnings in Q2 but signaled near-term headwinds — mid-year growth looks flat with downward Q3 guidance. Two independent analysts upgraded their price targets in early February, betting on stronger organic growth starting in FY27. Daniel Arias at Stifel raised his target from $60 to $65, while Daniel Markowitz at Evercore ISI bumped his from $62 to $68.
The analyst upgrades signal confidence in TECH's ability to reaccelerate after a soft 2025. Near-term pressure is real, but the shift in tone from both strategists suggests management's FY27 guidance is credible enough to justify 13–18% upside from current levels.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when TECH changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.